BR0116605A - Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono - Google Patents

Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono

Info

Publication number: BR0116605A
Authority: BR; Brazil
Prior art keywords: compound; disorders; treatment; central nervous; prophylaxis
Prior art date: 2000-12-27

Application number

BR0116605-0A

Other languages

English (en)

Portuguese (pt)

Inventor

Jonathan Mark Bentley

Michael John Bickerdike

Jacques Mizrahi

Paul Hebeisen

Timothy James Morley

Guy Anthony Kennett

Jean-Marc Plancher

Sean Lightowler

Hans Richter

Patrizio Mattei

Stephan Roever

Sven Taylor

Steven Paul Vickers

Original Assignee

Hoffmann La Roche

Vernalis Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-27

Filing date

2001-12-14

Publication date

2003-09-30

2000-12-27 Priority claimed from GB0031724A external-priority patent/GB0031724D0/en

2001-08-14 Priority claimed from GB0119820A external-priority patent/GB0119820D0/en

2001-12-14 Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche

2003-09-30 Publication of BR0116605A publication Critical patent/BR0116605A/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 5
238000000034 method Methods 0.000 title abstract 3
238000011282 treatment Methods 0.000 title abstract 3
208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
208000015114 central nervous system disease Diseases 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
238000011321 prophylaxis Methods 0.000 title abstract 2
201000002859 sleep apnea Diseases 0.000 title abstract 2
208000008589 Obesity Diseases 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR0116605-0A 2000-12-27 2001-12-14 Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono BR0116605A (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0031724A GB0031724D0 (en)	2000-12-27	2000-12-27	Indole derivatives
GB0119820A GB0119820D0 (en)	2001-08-14	2001-08-14	Indole derivatives
PCT/EP2001/014781 WO2002051844A1 (en)	2000-12-27	2001-12-14	Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands

Publications (1)

Publication Number	Publication Date
BR0116605A true BR0116605A (pt)	2003-09-30

Family

ID=26245498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0116605-0A BR0116605A (pt)	2000-12-27	2001-12-14	Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono

Country Status (16)

Country	Link
US (1)	US6610685B2 (2)
EP (1)	EP1347979B1 (2)
JP (1)	JP4094950B2 (2)
KR (1)	KR100539143B1 (2)
CN (1)	CN1250549C (2)
AR (1)	AR035722A1 (2)
AT (1)	ATE369368T1 (2)
AU (1)	AU2002228007B2 (2)
BR (1)	BR0116605A (2)
CA (1)	CA2432085C (2)
DE (1)	DE60129841T2 (2)
ES (1)	ES2291374T3 (2)
MX (1)	MXPA03005915A (2)
PE (1)	PE20020911A1 (2)
UY (1)	UY27097A1 (2)
WO (1)	WO2002051844A1 (2)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4460450B2 (ja)	2002-06-19	2010-05-12	ビオヴィトルム・アクチボラゲット（プブリクト）	新規化合物、その使用および製造法
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CL2004000826A1 (es)	2003-04-25	2005-03-04	Pfizer	Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) *	2003-06-26	2003-07-30	Hoffmann La Roche	Piperazine derivatives
ATE547404T1 (de)	2003-09-22	2012-03-15	Msd Kk	Piperidinderivate
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
MX2007005199A (es) *	2004-11-01	2007-05-11	Wyeth Corp	Indolizinas sustituidas y derivados como agentes del sistema nervioso central.
CN101094689B (zh)	2004-11-01	2013-06-12	安米林药品有限责任公司	治疗肥胖以及肥胖相关疾病和病症的方法
WO2007022123A2 (en)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610580B8 (pt)	2005-05-30	2021-05-25	Banyu Pharma Co Ltd	composto derivado de piperidina
JPWO2007018248A1 (ja)	2005-08-10	2009-02-19	萬有製薬株式会社	ピリドン化合物
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
WO2007024004A1 (ja)	2005-08-24	2007-03-01	Banyu Pharmaceutical Co., Ltd.	フェニルピリドン誘導体
WO2007029847A1 (ja)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	二環性芳香族置換ピリドン誘導体
EP1940842B1 (en)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja)	2005-10-21	2009-03-26	ノバルティスアクチエンゲゼルシャフト	レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (en)	2005-10-27	2012-01-04	Msd Kk	NEW BENZOXATHIIN DERIVATIVES
ES2381205T3 (es)	2005-11-10	2012-05-24	Msd K.K.	Derivado espiro aza-sustituido
DE602006010433D1 (de)	2005-12-09	2009-12-24	Hoffmann La Roche	Für die behandlung von obesitas geeignete tricyclische amidderivate
EP2727585A1 (en)	2006-05-16	2014-05-07	Takeda Pharmaceutical Company Limited	In-vivo screening method
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en)	2006-09-28	2009-10-01	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
ES2660173T3 (es)	2007-01-16	2018-03-21	Ipintl, Llc	Nueva composición para el tratamiento del síndrome metabólico
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2789338A3 (en)	2007-11-15	2015-01-14	Takeda Pharmaceutical Company Limited	Condensed pyridine derivate and use thereof
EP2264026A4 (en)	2008-03-06	2012-03-28	Msd Kk	ALKYLAMINOPYRIDINDERIVATE
WO2009119726A1 (ja)	2008-03-28	2009-10-01	萬有製薬株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2666036C (en)	2008-05-16	2017-09-12	Chien-Hung Chen	Novel compositions and methods for treating hyperproliferative diseases
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja)	2008-06-19	2011-12-01	Ｍｓｄ株式会社	スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en)	2008-07-30	2011-05-11	Msd K.K.	(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
EP2348857B1 (en)	2008-10-22	2016-02-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
US8329914B2 (en)	2008-10-31	2012-12-11	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
EP2510949A4 (en)	2009-12-11	2013-11-13	Astellas Pharma Inc	THERAPEUTICS FOR FIBROMYALGIA
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en)	2011-02-25	2013-09-30	Merck Sharp & Dohme	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
DK2681236T3 (en)	2011-03-01	2018-04-16	Synergy Pharmaceuticals Inc	PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru)	2012-08-02	2016-09-27	Мерк Шарп И Доум Корп.	Антидиабетические трициклические соединения
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
KR102431436B1 (ko)	2014-08-29	2022-08-10	테스 파마 에스.알.엘.	α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2018069532A1 (en)	2016-10-14	2018-04-19	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US20210052600A1 (en)	2017-12-27	2021-02-25	Takeda Pharmaceutical Company Limited	Therapeutic agents for stress urinary incontinence and incotinence of feces
CR20200621A (es) *	2018-06-21	2021-02-03	Hoffmann La Roche	Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
WO2021026047A1 (en)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
BR112023002957A2 (pt)	2020-08-18	2023-04-04	Merck Sharp & Dohme Llc	Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1247547A (en)	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
CA1328881C (en)	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
CA1270837A (en)	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
CA2035972C (en)	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5274143A (en)	1991-07-23	1993-12-28	Hoffmann-La Roche Inc.	Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
TW270114B (2)	1993-10-22	1996-02-11	Hoffmann La Roche
TW334423B (en) *	1993-10-22	1998-06-21	Hoffmann La Roche	Tricyclic 1-aminoethylpyrrole-derivatives
WO1998030548A1 (en)	1997-01-13	1998-07-16	Yamanouchi Pharmaceutical Co., Ltd.	5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES
US6004996A (en)	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
TR200100471T2 (tr)	1998-08-14	2001-07-23	F.Hoffmann-La Roche Ag	Lipaz inhibitörleri içeren farmasötik bileşimler
WO2000009123A1 (en)	1998-08-14	2000-02-24	F. Hoffmann-La Roche Ag	Pharmaceutical compositions containing lipase inhibitors and chitosan
GB9819035D0 (en) *	1998-09-01	1998-10-28	Cerebrus Res Ltd	Chemical compounds VII
NZ512765A (en)	1998-12-17	2003-10-31	Wyeth Corp	2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists
EP1132389A1 (en) *	2000-03-06	2001-09-12	Vernalis Research Limited	New aza-indolyl derivatives for the treatment of obesity

2001
- 2001-12-14 KR KR10-2003-7008679A patent/KR100539143B1/ko not_active Expired - Fee Related
- 2001-12-14 DE DE60129841T patent/DE60129841T2/de not_active Expired - Lifetime
- 2001-12-14 AT AT01989597T patent/ATE369368T1/de not_active IP Right Cessation
- 2001-12-14 WO PCT/EP2001/014781 patent/WO2002051844A1/en not_active Ceased
- 2001-12-14 AU AU2002228007A patent/AU2002228007B2/en not_active Ceased
- 2001-12-14 JP JP2002552939A patent/JP4094950B2/ja not_active Expired - Fee Related
- 2001-12-14 ES ES01989597T patent/ES2291374T3/es not_active Expired - Lifetime
- 2001-12-14 CA CA002432085A patent/CA2432085C/en not_active Expired - Fee Related
- 2001-12-14 US US10/017,978 patent/US6610685B2/en not_active Expired - Fee Related
- 2001-12-14 EP EP01989597A patent/EP1347979B1/en not_active Expired - Lifetime
- 2001-12-14 CN CNB018213510A patent/CN1250549C/zh not_active Expired - Fee Related
- 2001-12-14 BR BR0116605-0A patent/BR0116605A/pt not_active IP Right Cessation
- 2001-12-14 MX MXPA03005915A patent/MXPA03005915A/es active IP Right Grant
- 2001-12-21 AR ARP010106000A patent/AR035722A1/es not_active Application Discontinuation
- 2001-12-21 PE PE2001001298A patent/PE20020911A1/es not_active Application Discontinuation
- 2001-12-26 UY UY27097A patent/UY27097A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE60129841D1 (de)	2007-09-20
JP4094950B2 (ja)	2008-06-04
ES2291374T3 (es)	2008-03-01
CA2432085A1 (en)	2002-07-04
EP1347979A1 (en)	2003-10-01
UY27097A1 (es)	2002-07-31
DE60129841T2 (de)	2008-04-17
JP2004517852A (ja)	2004-06-17
PE20020911A1 (es)	2002-10-22
AU2002228007B8 (en)	2002-07-08
MXPA03005915A (es)	2003-09-10
KR20030063476A (ko)	2003-07-28
CA2432085C (en)	2009-02-24
EP1347979B1 (en)	2007-08-08
ATE369368T1 (de)	2007-08-15
CN1483034A (zh)	2004-03-17
KR100539143B1 (ko)	2005-12-26
CN1250549C (zh)	2006-04-12
US20020160997A1 (en)	2002-10-31
AU2002228007B2 (en)	2007-06-21
US6610685B2 (en)	2003-08-26
AR035722A1 (es)	2004-07-07
WO2002051844A1 (en)	2002-07-04

Legal Events

Date	Code	Title	Description
2009-09-29	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE 6A., 7A., E 8A. ANUIDADES.
2010-11-16	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.

Publication	Publication Date	Title
BR0116605A (pt)	2003-09-30	Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
BR0116201A (pt)	2004-03-02	Composto, processo para a preparação de um composto, composição farmacêutica que compreende o composto, utilização do composto, processo para o tratamento e profilaxia de distúrbios e para o tratamento de obesidade
BR0112918A (pt)	2003-07-01	Composto, utilização do mesmo, processo de tratamento de distúrbios, processo para a preparação de composto, composição farmacêutica que compreende esse composto, processo para preparar uma composição e processo de tratamento de obesidade em um ser humano
BR0012590A (pt)	2002-04-09	Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
BR0208111A (pt)	2004-03-02	Composto, utilização de um composto, processo de tratamento de distúrbios, processo para preparação de composto, composição farmacêutica que compreende o composto e processo de tratamento de obesidade
BR0212929A (pt)	2004-10-13	Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade
BR0209957A (pt)	2004-03-30	Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
BR0009486A (pt)	2002-01-02	Compostos que contêm uma amida, utilização desses compostos, composição farmacêutica, processo para o tratamento profilático ou terapêutico de, diabetes do tipo ii e processo para a preparação dos compostos
BR0112986A (pt)	2003-07-08	Compostos azabicìclicos, o respectivo preparo e a respectiva utilização como medicamentos, notadamente como antibacteriano
BR0213522A (pt)	2004-09-08	Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
BR0307441A (pt)	2005-01-04	Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade
BR0215312A (pt)	2004-12-07	Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
MY128659A (en)	2007-02-28	Novel aminodicarboxylic acid derivatives having pharmaceutical properties
SE0104340D0 (sv)	2001-12-20	New compounds
BR0211119A (pt)	2005-12-13	Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR9810592A (pt)	2000-09-12	Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
BR0107532A (pt)	2004-11-03	Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica
BR0108893A (pt)	2002-11-05	Composição farmacêutica, composto e processo de preparação de compostos
UY27592A1 (es)	2003-07-31	Nuevo uso
BG101582A (bg)	1998-01-30	Пиперазинови производни, съдържащите ги лекарствени форми, приложението им и метод за тяхното получаване
BRPI0512335A (pt)	2008-03-04	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0214243A (pt)	2004-12-21	Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
SE0202429D0 (sv)	2002-08-14	Novel Compounds
BRPI0111591B8 (pt)	2021-05-25	composto, composição farmacêutica, e, usos de um composto
BR0115045A (pt)	2004-02-03	Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade